DEP® gemcitabine........where are you

FYI

Abraxane® was developed by Abraxis
Abraxis started marketing Abraxane® in 2005
Celgene purchased Abraxis in 2010 for US2.9 billion
Bristol-Myers Squibb purchased Celgene in 2019
The loss of exclusivity for Abraxane® began in 2021 with the patent expiring in 2022. You can see the number start to taper off in 2021
Just by the by maybe BMS could ask Starpharma to develop a Dendrimer enhanced product version of Abraxane®
I have already done the numbers with Gemzar on another thread

Starpharma really is a hidden gem






Sales of  Abraxane®
2005 $133.7 million
2006 174.9
2007 324.7
2008 335.6
2009 314.5
2010 not sure of sales due to take over
2011 449
2012 427
2013 649
2014 848
2015 967
2016 973.4
2017 992
2018 1062
2019   1086 BMS purchase of Celgene
2020 1247
2021   1181 LOE (loss of exclusivity)
2022   214 million (1st quarter down 32%),  241 million (2nd quarter down 19%)

THE GENESIS AND TIMELINE FOR DEP® GEMBITABINE
DEP® Docetaxel has been used in combination with Gemcitabine in pre - clinical trials
DEP® Cabazitaxel has been used in combination with Gemcitabine in pre - clinical trials
DEP® Gemcitabine has been used in monotherapy in pre - clinical trials
DEP® Gemcitabine has been used in combination with Abraxane®
DEP® Docetaxel has been used in combination with Gemcitabine in Human trials. The first cohort enrolled was 10-12 patients in July 2020. It will be interesting to see the results from this combination which has been going for just on 2 years


DEP® gemcitabine has been filed at patent office. The first time this was made public - October 2019. .  I am not aware if the patent is still pending or approved. The process takes just under 3 years
Anyone with a bit of knowledge on patents

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=10&f=G&l=50&co1=AND&d=PG01&s1=starpharma&s2=gemcitabine&OS=starpharma AND gemcitabine&RS=starpharma AND gemcitabine

Nov16, 2018
DEP® docetaxel and DEP® cabazitaxel outperform in human pancreatic cancer model against leading pancreatic cancer therapies

Below are 4 graphics clearly demonstrating the superiority of Starpharma's DEP® docetaxel and DEP® cabazitaxel in monotherapies and combinations with gemcitabine compared with the leading pancreatic therapies of gemcitabine and Abraxane® (monotherapy and combination)

They say pictures paint a thousand words



Figure 1: Tumour volume vs time: DEP^® docetaxel and DEP^® cabazitaxel compared with gemcitabine and Abraxane^® as monotherapies in a mouse xenograft (human pancreatic cancer model)

AMAZING!!!








Figure 2: Tumour volume vs time: DEP^® docetaxel and DEP^® cabazitaxel in combination with gemcitabine compared with gemcitabine alone and in combination with Abraxane^® in a mouse xenograft (human pancreatic cancer model)


AMAZING!!!






Figure 3: Kaplan Meier Survival Curve comparing DEP^® docetaxel and DEP^® cabazitaxel versus other groups


AMAZING!!!









Figure 4: Kaplan Meier Survival Curve comparing DEP^® docetaxel + gemcitabine and DEP^® cabazitaxel + gemcitabine versus other groups


AMAZING!!!







Oct 31, 2019
DEP® gemcitabine outperforms Gemzar® (gembitabine) in human pancreatic cancer model


Figure 1:  Enhanced efficacy of DEP^® gemcitabine, compared to standard gemcitabine, in a human pancreatic cancer model (CAPAN-1)





Figure 2:  Enhanced efficacy of DEP^® gemcitabine + Abraxane^®, compared to standard gemcitabine + Abraxane^®, in a human pancreatic cancer model (CAPAN-1)





I look forward to finally seeing DEP^® gemcitabine in the clinic in combinations with Dep Docetaxel/Cabazitaxel, Abraxane.

So many choices